In several multi-center longitudinal studies involving hemodialysis cohorts, the administration of IV Levocarnitine demonstrated a significant reduction in the ESA Resistance Index. Numerical data from recent trials indicates: Anemia Management: Patients receiving IV Levocarnitine showed an average 15% to 25% reduction in the required dose of Erythropoietin (EPO) to maintain target hemoglobin levels
MANUFACTURER: Sponser Sport Food AG, CH-8832 Wollerau, Switzerland
Over a BPC-157 protocol, you want to see it come back down, indicating the destructive phase is resolving and constructive healing is dominant
Nonrandomized evaluations, pharmacokinetic studies, animal/laboratory studies, and general reviews were excluded, and duplicated publications reporting the same groups of patients were also excluded (Figure S1 in Supplementary Material available online at 2.3
T.FujimuraM.MaT.NoshitaN.FilizF.BollenA